Abstract
CADM1 is a major receptor for the adhesion of mast cells (MCs) to fibroblasts, human airway smooth muscle cells (HASMCs) and neurons. It also regulates E-cadherin and alpha6beta4 integrin in other cell types. Here we investigated a role for CADM1 in MC adhesion to both cells and extracellular matrix (ECM). Downregulation of CADM1 in the human MC line HMC-1 resulted not only in reduced adhesion to HASMCs, but also reduced adhesion to their ECM. Time-course studies in the presence of EDTA to inhibit integrins demonstrated that CADM1 provided fast initial adhesion to HASMCs and assisted with slower adhesion to ECM. CADM1 downregulation, but not antibody-dependent CADM1 inhibition, reduced MC adhesion to ECM, suggesting indirect regulation of ECM adhesion. To investigate potential mechanisms, phosphotyrosine signalling and polymerisation of actin filaments, essential for integrin-mediated adhesion, were examined. Modulation of CADM1 expression positively correlated with surface KIT levels and polymerisation of cortical F-actin in HMC-1 cells. It also influenced phosphotyrosine signalling and KIT tyrosine autophosphorylation. CADM1 accounted for 46% of surface KIT levels and 31% of F-actin in HMC-1 cells. CADM1 downregulation resulted in elongation of cortical actin filaments in both HMC-1 cells and human lung MCs and increased cell rigidity of HMC-1 cells. Collectively these data suggest that CADM1 is a key adhesion receptor, which regulates MC net adhesion, both directly through CADM1-dependent adhesion, and indirectly through the regulation of other adhesion receptors. The latter is likely to occur via docking of KIT and polymerisation of cortical F-actin. Here we propose a stepwise model of adhesion with CADM1 as a driving force for net MC adhesion.
Introduction
Mast cells (MCs) are highly specialised secretory cells, which serve as a first-line of defence against infections and environmental toxins. They are involved in the induction of an immune response to various pathogens and are also an integral part of the adaptive immune response [1], [2]. MCs are notorious for their roles in allergy, asthma and anaphylaxis, they also contribute to the pathophysiology of diseases in many tissues including idiopathic pulmonary fibrosis, rheumatoid disease and atherosclerosis [3], [4]. They play a central role in a mouse model of chronic asthma by inducing major pathological changes, including airway hyper-responsiveness and airway remodelling [5].
MCs possess a complex set of adhesion receptors which facilitate the migration of their progenitors from the bone marrow into various tissues where they mature and interact with various cell types and extracellular matrices (ECMs). Human MCs express a variety of adhesion receptors, including alpha2–5, alphaV, alphaM, alphaX, beta1–3 integrins, CD44, ICAM1, and cell adhesion molecule-1 (CADM1), involved in cell-ECM and cell-cell interactions [6]–[12]. Only E-cadherin is detected in human MCs by some researchers [13], [14], but not others [9], [15]. It was not found in HLMCs (Bradding, unpublished data). However, there is marked heterogeneity with respect to MC receptor expression between species, between cells in different organs, and even between cells within the same organ [16].
CADM1 is implicated in MC adhesion to fibroblasts, airway smooth muscle cells (HASMCs) and nerves [12], [17]–[19]. Adhesion of human lung MCs (HLMCs) to lung structural cells such as HASMCs and human lung fibroblasts (HLFs) and their consequent interactions have important physiological consequences on survival, proliferation, phenotypic changes and activation with mediator release of mast cells on the one hand, and augmented contractile activity and pro-fibrotic changes in HASMCs and HLFs on the other hand [3], [19]–[22].
CADM1 belongs to a gene family of cell-cell adhesion receptors, which also include CADM1-4, PVRL1-4, PVR, and CRTAM, as annotated by Ensembl [23]. CADM1 is essential for human health and is implicated in several diseases, such as cancer, autism spectrum disorder and venous thrombosis [24]–[26]. In mice, the CADM1 gene is implicated in cancer, radiation-induced lung fibrosis and bone structure [27]–[29]. CADM1 mediates cell-cell adhesion via interactions with counter-receptors, all of which belong to the same family [30]–[33]. In addition, CADM1 affects the localisation of other adhesion receptors, such as E-cadherin and the alpha6beta4 integrin on the cell surface of epidermal and epithelial cells, respectively [34], [35]. Similarly, other members of the CADM gene family are involved in recruitment of cell-cell and ECM adhesion receptors to the cell membrane, and the assembly and stabilisation of adhesion complexes [36], [37].
CADM1 is expressed as several functional isoforms in HLMCs [38], [39]. The SP4 isoform, containing exons 1–8/11–12, is the principal functional isoform in the neoplastic MC line HMC-1 [38], [39]. HLMCs also express the longer SP1 (exons 1–9/11–12) and SP6 (exons 1–12) isoforms in addition to SP4 [38], [39]. Our previous studies demonstrated differences in the survival and adhesion of mast cells overexpressing either only SP4 or mixed isoforms. SP1 plays a dominant-negative role in survival compared to SP4 [38]. The long SP1 and SP6 isoforms, expressed on the background of predominant SP4, interfere with MC adhesion to human lung fibroblasts (HLFs) or homotypic MC aggregation [19], [38], [39]. CADM1 is a major cell adhesion receptor for the adhesion of HLMCs to HASMCs and HLFs, but CADM1 blocking and downregulation do not abolish adhesion completely [12], [19]. Since both HLFs and HASMCs build ECM around cells, which provide an additional adhesion scaffold on the cell surface, ECM adhesion receptors are expected to contribute to HLMC adhesion to these cell types. Indeed, the alpha5beta1 integrin is involved in the long-term interactions of HLMCs with HASMCs [40]. Moreover, the alphaV integrin and CD44 are also implicated in the adhesion of HLMCs to HASMCs under inflammatory conditions [41].
Several lines of evidence suggest that CADM1 is involved in ErbB3/ErbB2 signal transduction and assembly of CADM1/alpha6beta4 integrin complexes on the cell membrane [35], [42]. CADM1 is essential for MC survival [20], [38], [43], and a link between CADM1 and MC survival in the absence of adhesion suggests potential CADM1-mediated constitutive signalling [38]. As an adhesion receptor, CADM1 is likely to be involved in outside-in signalling.
The CADM1 intracellular domain has FERM-binding and PDZ-binding motifs, that potentially act as a molecular scaffold for the formation of signalling complexes. The CADM1 FERM–binding site interacts with 4.1B, 4.1G and 4.1N [44]–[46]. Focal adhesion kinase p125 is another protein, which binds to the FERM–binding site of CADM1 [47]. The CADM1 PDZ-binding site interacts with a variety of PDZ proteins, including MAGUK proteins (MPP1, MPP3, MPP6 and CASK), syntenin, protein tyrosine phosphatase PTPN13 and Tiam1 [31], [42], [48]–[51]. In addition, the CADM1 extracellular domain binds the receptor tyrosine kinases ErbB2/3 and the alpha6beta4 integrin [35], [42]. Among these CADM1-binding proteins only 4.1N, 4.1G, MPP1, CASK, syntenin and FAK are expressed at the mRNA level [syntenin>MPP1>4.1N, 4.1G> CASK, FAK] in human MCs [14]. The CADM1-binding 4.1 proteins and CASK are linked to the actin cytoskeleton, providing a connection between CADM1 and the actin cytoskeleton [44], [52]. Furthermore, the receptor tyrosine kinase Kit, critical for the survival of human MCs, co-precipitates with CADM1 [12].
In summary, substantial evidence indicates that CADM1 is likely to affect the formation of membrane complexes, cell signalling and, thereby, the function of other adhesion receptors in HLMCs. We have examined this hypothesis by studying the role of CADM1 in MC adhesion to ECM, intracellular signalling and the polymerisation of filamentous actin. We show for the first time that CADM1 downregulation decreases MC adhesion to ECM and that modulation of CADM1 causes changes in surface Kit levels, tyrosine phosphorylation and the actin cytoskeleton. Our data imply that MC adhesion involves cooperating adhesion receptors which function in a stepwise manner, with a critical role for CADM1.
Materials and Methods
Cell Culture
The human MC line HMC-1.1 (KIT V560G) [53] was cultured in IMDM with 10% foetal bovine serum. HLMCs were isolated from healthy lung obtained at surgery for carcinoma using anti-CD117-coated Dynabeads [10]. HLMCs were cultured in DMEM supplemented with 10% FCS, and cytokines (100 ng/ml SCF, 50 ng/ml IL-6, and 10 ng/ml IL-10) as described previously [20]. Stabilised (1–2)-week old HLMCs with a final purity of >99%, were used for adenoviral transduction. HASMCs were isolated using explant culture of ASM bundles and cultured at passages 3–5 in DMEM supplemented with 10% FBS, antibiotic/antimycotic agents and non-essential amino acids as previously described [54]. They expressed ASMC-specific antigens alpha-smooth muscle actin and smooth muscle myosin with efficiency 93% and 60%, respectively. All patients gave written informed consent and the study of primary human lung mast cells and human airway smooth muscle cells was approved by the Leicestershire, Northamptonshire and Rutland Research Ethics Committee.
Adenoviral transduction
The CADM1 cDNAs and ShRNA in adenovirus particles (BioFocus, Leiden, the Netherlands) and transduction conditions were described previously [38]. Adenoviral particles with GFP cDNA and luciferase shRNA (LucSh) were used as controls. Sh5 alone or a mix of Sh3/Sh4/Sh5, denoted here as Shm, was used for CADM1 downregulation. HMC-1 cells were transduced for 6 days. HLMCs were transduced for 4 days to prevent strong cell-cell aggregation of transduced cells which occurs at 6 days [38], thus ensuring that single cell suspensions were used in experiments.
FACS Analysis
Cells (105/vial) were washed in PBS, fixed in 4% formaldehyde in PBS and stained with 1 µg/ml chicken anti-CADM1 3E1 IgY mAb (Medical & Biological Laboratories, Japan) or IgY control, followed by Cy5-conjugated anti-IgY Ab (Millipore, UK). Surface Kit was measured using 1/50 PE-conjugated mAb YB5.B8 and control PE-conjugated IgG1 (BD Pharminogen, UK). FITC-conjugated phalloidin (Invitrogen, Life Technologies, UK) was used to quantify actin filaments (F-actin) according to the manufacturer’s recommendation. Stained cells were washed twice to remove non-specific staining. Fluorescence was examined using a FACSCanto II flow cytometer and FACSDiva2 software (BD Biosciences). Two/three biomarkers were measured simultaneously in the same samples. Geometric means were used to quantify levels of surface expression of CADM1 and Kit, and F-actin.
Protein Analysis
Protein extracts were prepared using NP40 detergent (Invitrogen) extraction with wide spectrum inhibitors of proteases and protein phosphatases. SDS–PAGE, western blotting and protein quantification were performed as described previously [38]. When possible, blots were cut into horizontal strips with proteins of a particular range of molecular weights, probed with appropriate antibodies. Alternatively, whole blots were sequentially probed with antibodies from different species. Antibodies against CADM1 (3E1 IgY mAb, Medical & Biological Laboratories, Japan), Kit (E1, Santa Cruz Biotechnology), Kit pY823 and pY936 (44–498G and 44–500G Abs, Biosource, Life Technology, UK), phosphotyrosine (mAb pY99 sc-7020, Santa Cruz Biotechnology, Germany) and beta-actin HRP-conjugated mAb C4 (Santa Cruz Biotechnology, Germany) were used in this study.
Mast Cell Adhesion
Adhesion assays were performed as previously described with minor modifications [10], [12], [19], [39]. HASMCs were prepared as cells from three independent donors, mixed in equal numbers. HASMCs were seeded at 104 cells/well in 96 well plates in growth medium. When cells reached confluence, the medium was replaced with DMEM supplemented with insulin/transferrin/sodium selenite (ITS-3; Sigma-Aldrich, UK) for 3 days before use. HMC-1 cells, labelled with 5 µM calcein AM (Invitrogen, Life Technologies, UK) according to manufacturer’s recommendation prior to adhesion [19], [39] (104 cells/0.1 ml/well), were used for adhesion to the HASMC monolayer for 30 or 60 min in the presence or absence of 5 mM EDTA. Medium and non-adherent cells were discarded. Adherent HMC-1 cells were detected by fluorescence [19], [39].
When inhibitory mAbs were used, HMC-1 cells were pre-incubated for 15 min with 10 µg/ml 9D2 IgY mAb against CADM1 (Medical & Biological Laboratories, Japan) or for 30 min with 6.5 µg/ml mAb against alpha5beta1 integrin (MAB1969, Chemicon, Millipore, UK) prior to the adhesion assay, as described previously [12], [40]. For adhesion to fibronectin (Sigma-Aldrich, UK), plates were coated with 2 µg/50 µl/well overnight and washed with PBS [40]. For adhesion to ECM, plates with HASMCs were frozen, washed on ice with a hypotonic buffer, containing 10 mM Tris pH7.5, 0.1 mM CaCl2, and 0.1% BSA, followed by the same buffer with 0.25% NP-40, followed by washes with PBS and blocking with 0.5% BSA in PBS on ice, as previously described [55].
Fluorescence Microscopy
Cells were labelled as for FACS, placed on a glass slides, with or without coverslips, and analysed on an Olympus IX81 FV1000 confocal laser scanning microscope, using a 60×1.35 NA UPlanSAPO Olympus objective, image size of 1024×1024 pixels and a zoom of 3. Z-series of FITC (Ext = 488 nm, Em = 500–545 nm), PE (Ext = 559, Em = 575–620 nm) and Cy5 (Ext = 635 nm, Em = 655–755 nm) were taken in sequential scan mode with collection of transmitted light of the 488 nm scan. Images were deconvolved using Huygens Essential deconvolution software (SVI, The Netherlands). The 3D reconstructions were generated and the Z axial distance and minimal and maximal cross-sectional distances were measured using Imaris software (Bitplane, Switzerland). The colocalisation module of this software package was also used to calculate the thresholded Manders’ colocalisation coefficients M1/M2 in the colocalised volume for F-actin or Kit over CADM1.
The maximal length of actin filaments was measured as the means of four longest distances between crossed filaments and the means of four longest filaments from the cell membrane for each examined HMC-1 cell and HLMC, respectively, using ImageJ 1.46 (rsb.info.nih.gov/ij/). The means were then calculated for each group of ten transduced cells. More details are shown in Fig. S3 and Fig. S4.
Data Analysis
Analysis was performed using GraphPad Prism 5 software. All data are presented as the mean ±SE. Differences among the groups were analysed using a one-way ANOVA, followed by the Dunnett’s test to determine whether the groups were different from a control group, or the Bonferroni’s test to compare multiple groups. Groups of data with non-parametric distribution or non-equal variances were analysed by the Kruskal-Wallis test, followed by the Dunn’s multiple comparison test. Pearson’s and Spearman’s tests were used to analyse correlations. Analysis of biomarker expression in a generalised linear model was performed using SPSS (PAWS18, IBM).
Results
Mast Cell Adhesion to HASM Cells and their ECM is Time-dependent
Since MC adhesion to HASMCs involves cell-cell adhesion and potentially adhesion to ECM, present on the cell surface and between the cells, we examined adhesion in conditions which permitted estimation of divalent metal cation-dependent integrin involvement. Firstly, we investigated the time-course of HMC-1 adhesion to HASMCs and their ECM. Secondly, EDTA was used to block integrins, the only ECM adhesion receptors which are dependent on divalent ions. EDTA also inhibits cadherins, but the expression of E-cadherin in human MCs is controversial (see above), and HASMCs do not express E-cadherin [56], hence cadherins are not involved in MC adhesion to HASMCs. CADM1 belongs to the family of Ca2+-independent cell-cell adhesion receptors, which are not affected by EDTA. The neoplastic human MC line HMC-1 was used in these experiments, since it displays a similar pattern of adhesion receptors and adhesion to those of HLMCs [12], [15], [19].
Net adhesion of HMC-1 cells to HASMCs was 56±5% and 92±8% after 30 and 60 min, respectively ( Fig. 1A ). Thus, adhesion increased progressively over 60 min, almost reaching 100%. Adhesion of HMC-1 cells to HASMCs in the presence of EDTA was 42±4% and 55±3% after 30 and 60 min, respectively ( Fig. 1A ), indicating that integrins, inhibited by EDTA, contributed little to adhesion at 30 min, but contributed significantly to net adhesion (∼41%) after 60 min. Adhesion of HMC-1 cells to HASMC ECM was 36±3% and 70±5% after 30 and 60 min, respectively ( Fig. 1A ). EDTA reduced adhesion to ECM to 22±2% and 22±2% after 30 and 60 min, respectively ( Fig. 1A ). Again divalent cation-dependent integrins contributed more to net adhesion after 60 min (∼69%) compared to 30 min. Thus, adhesion to HASMCs appears to involve both cell-cell and cell-ECM adhesion receptors, with the latter involved mostly at an advanced stage of adhesion.
CADM1 Regulates Adhesion of HMC-1 Cells to HASMCs and ECM
Next we examined adhesion of HMC-1 cells overexpressing the SP4 CADM1 isoform and cells with downregulated CADM1 in the presence or absence of EDTA as above. CADM1 overexpression increased surface CADM1 expression, while RNA interference reduced CADM1 expression (Fig. S1).
We have shown previously that CADM1 overexpression does not increase MC adhesion to HASMCs, because the binding is limited by co-receptors expressed on HASMCs, but CADM1 downregulation decreases adhesion to HASMCs [19]. Adhesion of SP4-overexpressing cells to HASMCs was 45±2% and 99±5% after 30 and 60 min, respectively, whereas adhesion of CADM1-downregulated cells (Sh5 group) in the same conditions was 20±1% and 37±1%, respectively ( Fig. 1B ). Thus, CADM1 downregulation decreased adhesion to HASMCs after 30 and 60 min, confirming a major role for CADM1 in MC adhesion to HASMCs at both initial and more advanced stages, in agreement with our previously reported data [19].
In the presence of EDTA, adhesion of SP4-overexpressing HMC-1 cells to HASMCs was reduced to 22±2% and 64±3% after 30 and 60 min, respectively; whereas adhesion of HMC-1 cells with downregulated CADM1 in the presence of EDTA was 6±1% and 13±1%, respectively ( Fig. 1B ). Thus, EDTA again reduced adhesion of CADM SP4-overexpressing cells and CADM1-downregulated cells after 60 min, suggesting integrin involvement. This integrin-dependent contribution to the net adhesion of SP4-overexpressing HMC-1 cells to HASMCs was ∼36% after 60 min. However, it contributed ∼64% to the net adhesion of HMC-1 cells with downregulated CADM1 ( Fig. 1B ). Thus, downregulation of CADM1 markedly increased the relative contribution of other adhesion receptors, e.g. divalent cation-dependent integrins, in the adhesion of HMC-1 cells to HASMCs.
Next we examined the adhesion of CADM1-modulated HMC-1 cells to the ECM of HASMCs. Adhesion of SP4-overexpressing HMC-1 cells to ECM was 25±2% and 55±4% after 30 and 60 min, respectively, whereas adhesion of CADM1-downregulated cells in the same conditions was 7±1% and 17±2%, respectively ( Fig. 1C ). EDTA further reduced ECM adhesion of SP4-overexpressing cells to 18±2% and 28±3% after 30 and 60 min, respectively, and adhesion of cells with downregulated CADM1 to 2±0% and 6±1% after 30 and 60 min ( Fig. 1C ), respectively. Importantly adhesion of SP4-overexpressing cells was always higher than adhesion of cells with downregulated CADM1 in the same conditions, despite the fact that CADM1 is not an ECM adhesion receptor.
These surprising data implied that CADM1 is involved in the ECM adhesion of HMC-1 cells either directly or indirectly. If CADM1 directly recognises specific ECM molecules, CADM1 inhibition by specific adhesion-blocking antibody would be expected to reduce adhesion to its substrate. If CADM1 does not interact with ECM directly, it may regulate ECM adhesion receptors by other mechanisms. In the latter case, CADM1-inhibitory antibody would not affect adhesion to ECM. To examine these alternative hypotheses, we studied adhesion of HMC-1 cells in the presence of CADM1-inhibitory antibody 9D2 [12] and with an alpha5beta1 integrin-inhibitory Ab, used as a negative control in adhesion to fibronectin. The alpha5beta1 integrin-inhibitory Ab and EDTA decreased HMC-1 adhesion to fibronectin from 35±3% in control to 22±2% and 19±1% respectively, but blocking CADM1 was without effect ( Fig. 1D ). Adhesion to HASMC ECM was not reduced by CADM1-blocking antibody, but was reduced by EDTA to 15±2% from 43±2% in the control ( Fig. 1E ). These data suggest that CADM1 is likely to regulate ECM adhesion indirectly, since CADM1 inhibition did not affect adhesion to ECM.
Collectively, these data indicated that 1) MC adhesion to HASMCs involves both cell and ECM adhesion receptors; 2) CADM1 is a major MC adhesion receptor providing fast initial cell-cell adhesion; 3) divalent cation-dependent integrins are major ECM adhesion receptors which contribute more significantly to MC-ECM adhesion at a more advanced stage; 4) CADM1 expression levels markedly influence the function of MC ECM adhesion receptors.
CADM1 Influences Surface Kit Levels in Human Mast Cells
Cell adhesion via integrins requires phosphotyrosine signalling and integrin anchoring to the actin cytoskeleton [57]. Since CADM1 is linked to the actin cytoskeleton and interacts with Kit, which cross-activates integrins in MCs [58], we investigated whether CADM1 affects expression of surface Kit and assembly of actin filaments in HMC-1 cells.
Surface CADM1 was significantly modulated by SP4 and SP1 overexpression or RNA interference in HMC-1 cells, but no statistically significant changes were detected in the surface Kit levels or F-actin (Fig. S1). To increase statistical power for these analyses, control groups (LucSh shRNA and non-transduced cells) and CADM1-downregulated groups (Sh5 and Shm) were combined. The total dataset was normalised to either the SP4 group (a larger dataset, Fig. 2 ) or the control group (a smaller dataset, Fig. S2). Surface CADM1 was increased in SP4- and SP1-overexpressing cells to 138±11% and 146±3%, respectively, compared to the combined control group (100%), whereas RNA interference reduced CADM1 to 72±3% (Fig. S2A).
Kit levels on the cell surface slightly varied among the groups of transduced cells, but no statistical differences were found ( Fig. 2A , Fig. S2A). However, when we examined the potential relationship between surface expression levels of these proteins, surface Kit levels correlated positively with modulated CADM1 levels ( Fig. 2B ). The larger dataset for Kit ( Fig. 2B ), which included both SP1 and SP4 overexpression, displayed a non-parametric distribution and could not be analysed further. Since HMC-1 cells express predominantly one functional isoform SP4, all groups with modulated CADM1, apart from the SP1 group, expressed only this isoform. The data points for SP1 were clustered towards one end ( Fig. 2B ). The smaller dataset also showed that surface Kit was strongly associated with changes in surface CADM1 (Fig. S2B). CADM1 was responsible for ∼46% of surface Kit (R2 = 0.46) in HMC-1 cells (Fig. S2B).
CADM1 Influences Actin Polymerisation in Human Mast Cells
F-actin was increased in SP4-overexpressing cells compared to the control group ( Fig. 2 , Fig. S2A). F-actin strongly correlated with modulated CADM1 ( Fig. 2C ). Regression analysis of the larger dataset for CADM1 and F-actin showed that CADM1 is responsible for 31% of F-actin assembly (r2 = 0.307) in HMC-1 cells ( Fig. 2C ). When we examined the data for SP1 and SP4 isoforms they were again distinct as shown in the graph in Fig. 2C . A linear regression model predicted that both CADM1 (a numerical variable) and isoforms SP4 or SP1 (a categorical variable) had a major effect on F-actin (P = 0.000 for CADM1 and P = 0.001 for isoforms). The smaller dataset showed a trend of a correlation between F-actin and CADM1 (P = 0.089, Fig. S2B).
CADM1 Expression Influences Tyrosine Phosphorylation in Human Mast Cells
Since modulation of CADM1 induced changes in surface Kit levels, Kit-mediated tyrosine phosphorylation was likely to be modulated as well. Therefore, we examined phosphotyrosine signalling in cells with CADM1 either overexpressed or downregulated. In these experiments, total CADM1 was increased to 187±24% in the SP4-overexpressing group and reduced to 31±6% in the CADM1-downregulated Shm group compared to the LucSh control ( Fig. 2D–2E , Fig. S2C). Conversely, modulation of surface CADM1 was smaller than modulation of total CADM1 in agreement with our previous data [38], indicating that CADM1 delivery to the cell surface is likely to be regulated. CADM1 modulation did not influence total levels of Kit or beta-actin ( Fig. 2D–2E , Fig. S2C) in agreement with our previous results [38]. CADM1 SP4 overexpression reduced phosphorylation of Kit Tyr-823 in the kinase active site to 71±5%, whereas CADM1 downregulation increased autophosphorylation of Tyr-936 to 153±24% ( Fig. 2D–2E , Fig. S2C). CADM1 downregulation also increased tyrosine phosphorylation of several protein bands with molecular weights ∼58–63 kDa to176±5% ( Fig. 2D–2E ).
In summary, these data show that CADM1 in HMC-1 contributes to 1) docking of Kit to the cell surface, 2) the amounts of F-actin and 3) tyrosine phosphorylation of Kit and other proteins.
CADM1 Regulates Actin Cytoskeleton and Cell Signalling in Human Lung Mast Cell Cells
Next we examined whether CADM1 modulation affects the amount of F-actin and cell signalling in HLMCs. Surface CADM1 was overexpressed to 251±54% or downregulated to 55±7% in several populations of HLMCs ( Fig. 3A–3B ), as described previously [19]. Modulation of CADM1 did not significantly change levels of F-actin ( Fig. 3C ), but F-actin was reduced in all four HLMC populations with reduced CADM1 and there was a correlation between downregulated CADM1 and F-actin ( Fig. 3D ). In two populations of HLMCs, CADM1 downregulation decreased tyrosine phosphorylation of 58–60 kDa proteins ( Fig. 3E–3F ). Since Kit phosphorylation is not detectable in non-stimulated HLMCs, it was not studied here. Thus, we have evidence of CADM1-mediated effects on the actin cytoskeleton and tyrosine phosphorylation in both HLMCs and the human mast cell line HMC-1.
CADM1 Downregulation Influences Cell Shape and Increases the Length of F-actin Filaments in Human Mast Cells
To examine the consequences of CADM1-dependent modulation of F-actin assembly and surface Kit, HMC-1 cells co-stained for surface CADM1, surface Kit and F-actin were examined microscopically. Cells in suspension between glass-slides and coverslips had the shape of crumpets ( Fig. 4A , Video S1, S2, S3). The horizontal cross-sectional measurements were similar in all transduced groups, but the cell height (Z-axial) measurements were higher in the cells with downregulated CADM1 (6.6±0.7 µm) compared to those in the SP4-overexpressing cells (3.9±0.3 µm), whereas there was no difference between the LucSh control cells (4.9±0.6 µm) and SP4-overexpressing cells ( Fig. 4B ).
Next we studied cortical actin filaments in HMC-1 cells with modulated CADM1. Cortical F-actin in cells with downregulated CADM1 looked strikingly different compared to the control LucSh-transduced cells or SP4-overexpressing cells ( Fig. 5A , Fig. S3, Video S1, S2, S3). F-actin filaments appeared as numerous short points on the cell surface in the SP4-overexpressing and control cells, whereas they were a network of sparse, widely separated long filaments in cells with downregulated CADM1. The maximal length of F-actin filaments was significantly higher in the CADM1 downregulated group (1.78±0.19 µm) compared to that in the SP4 and LucSh groups (0.92±0.11 µm and 1.06±0.09 µm, respectively, Fig. 5B ).
In order to estimate colocalisation of CADM1 with F-actin and Kit, we measured colocalisation coefficients (for details see [59]–[61]). The thresholded Manders’ coefficients M1 and M2 are often interpreted as co-occurrence of measured biomarkers [61]. Surprisingly, there was little colocalisation between CADM1 and F-actin in merged images ( Fig. 5A , Video S1, S2, S3). The thresholded Manders’s coefficient M1 for colocalisation of F-actin with CADM1 was 0.46±0.06, 0.64±0.06 and 0.42±0.07 for the SP4, LucSh and Shm groups of cells, respectively ( Fig. 5C ), indicating medium colocalisation of the F-actin signal with CADM1, particularly increased in control LucSh cells. The Manders’s coefficient M2 for colocalisation of CADM1 with F-actin was 0.41±0.07, 0.11±0.03 and 0.23±0.06 for the SP4, LucSh and Shm groups of cells, respectively ( Fig. 5C ). It was significantly increased in the SP4 group compared with control LucSh cells. Colocalisation of F-actin with CADM1 (M1) was higher than colocalisation of CADM1 with F-actin (M2, Fig. 5C ).
There was colocalisation between Kit and CADM1 on the cell surface in merged images ( Fig. 6A, 6C ) in agreement with previously published data [62]. The thresholded Manders’ coefficient M1 for colocalisation of Kit with CADM1 was reasonably high: 0.59±0.05, 0.76±0.04 and 0.62±0.09 in SP4-overexpressing, LucSh- and Shm-transduced cells respectively ( Fig. 6B ), indicating that more than 50% of the Kit signal in these optical sections colocalised with CADM1. Manders’s coefficient M2 for colocalisation of CADM1 with Kit was 0.47±0.07, 0.25±0.04 and 0.28±0.07 in SP4-overexpressing, LucSh- and Shm-transduced cells, respectively ( Fig. 6B ). Colocalisation of Kit with CADM1 was therefore higher than colocalisation of CADM1 with Kit in control cells. Colocalisation of F-actin or Kit with CADM1 (M1) was higher than colocalisation of CADM1 with F-actin or Kit (M2) in control cells ( Fig. 6B ).
Next we examined HLMCs from donor D682 with modulated CADM1 microscopically. This time cells were in suspension on glass slides without coverslips. Again cortical F-actin looked strikingly different in cells with downregulated CADM1 ( Fig. 7A , Fig. S4). The maximal length of F-actin filaments was significantly higher in the CADM1 downregulation group (2.07±0.08 µm) compared to that in the SP4 and LucSh groups (1.34±0.04 µm and 1.27±0.05 µm, respectively, Fig. 7B ). Thus, the cortical actin filaments were shorter in controls and SP4-overexpressing cells than in cells with reduced CADM1 in both neoplastic HMC-1 cells and HLMCs. Similar to HMC-1 cells, some limited co-localisation of CADM1 with actin filaments could be seen as a yellow colour particularly in control cells and cells with reduced CADM1 ( Fig. 7A ). The HLMCs had round shapes, but no differences between the transduced groups were observed in cell dimensions ( Fig. 7C ).
Discussion
Cell adhesion is a complex process and involves various adhesion receptors; it is also influenced by growth factor receptor tyrosine kinases [57], [63]. Current models of adhesion involve cooperation between ECM adhesion receptors integrins and syndecans [57]. Cell-cell adhesion receptors nectins (PVRL) and CD155 (PVR) of the CADM gene family recruit integrins and cadherins to the cell membrane and promote the assembly and stabilisation of adhesion complexes [36], [37]. MCs express a complex set of adhesion receptors, including ECM adhesion receptors (CD44, integrins) and cell-cell adhesion receptors (CADM1, ICAM-1) [6]–[11], [17]. Activation of the receptor tyrosine kinase Kit is known to increase integrin engagement in MCs, whereas Kit inhibition reduces it [58], [64], [65].
Here we show for the first time that CADM1 plays a key role in the regulation of divalent cation-dependent integrin receptors, contributing to MC adhesion to ECM. We also show for the first time that CADM1-promotes Kit docking to the cell surface and polymerisation of cortical F-actin in MCs and affects tyrosine signalling. All these factors are critical for integrin function and are likely to play roles in CADM1-mediated adhesion.
In this study we have confirmed that adhesion of human MCs to HASMCs involves CADM1, in agreement with previously published data [12], [19]. We also show for the first time that MC adhesion to HASMCs involves adhesion to their ECM. We found that CADM1 provides adhesion at both 30 and 60 min, but the contribution of divalent ion-dependent integrins to ECM adhesion becomes relatively greater at 60 min compare to 30 min. This is in agreement with time-course data on integrin-dependent MC adhesion to vitronectin and fibronectin, which reaches maximal values after 1 h [66], [67]. The role of other ECM receptors which are not dependent on divalent ions, such as CD44, appears to be relatively small in human MC adhesion to HASMCs and their ECM in our experimental conditions.
Here we demonstrate that these adhesion receptors work stepwise: CADM1 was responsible for both initial adhesion and more advanced adhesion to HASMCs, whereas integrins contributed to adhesion mostly at an advanced stage. Unexpectedly downregulation of CADM1 resulted in reduced ECM adhesion. No ECM proteins have been identified among CADM1-interacting proteins to-date (see http://www.ncbi.nlm.nih.gov/gene/23705) [68]. Inhibition of CADM1 with the adhesion-blocking mAb 9D2 did not affect MC adhesion to either ECM or fibronectin, suggesting that it is the CADM1 levels, not CADM1 binding, which are important. Hence, CADM1 is unlikely to bind to ECM directly (although not impossible and requires further investigation), but it is more likely to regulate ECM adhesion receptors in MCs indirectly.
Interactions between CADM1 family receptors and other adhesion receptors have been described previously [36], [37]. CADM1 is known to interact specifically with the hemidesmosomal alpha6beta4 integrin, but not alpha5beta1 or alpha6beta1 integrins, in colorectal adenocarcinoma Caco-2 cells [35]. In contrast to our results, CADM1 modulation in those cells did not affect adhesion to ECM substrates laminin-332 or matrigel [35]. Human MCs express predominantly beta1 integrins and do not express alpha6beta4 integrin [14]. Therefore, we studied whether CADM1 affects ECM adhesion via other mechanisms, such as tyrosine signalling and actin polymerisation, which are essential for integrin activation and anchoring, respectively. We also hypothesised that CADM1 may influence activity of other adhesion receptors via interactions with Kit on the cell surface.
To investigate this, we examined whether CADM1 modulation would affect cortical filamentous actin and surface Kit levels using FACS analysis. In neoplastic HMC-1 cells, the levels of surface Kit and F-actin displayed linear dependence on CADM1 levels. CADM1 was responsible for a half of surface Kit and a third of the F-actin levels in these cells. Moreover, CADM1 levels markedly influenced tyrosine phosphorylation in HMC-1 cells. CADM1 upregulation reduced tyrosine-823 phosphorylation in the kinase domain of Kit, suggesting downregulation of Kit activity. In contrast, CADM1 downregulation augmented autophosphorylation of the tyrosine-936, indicating increased kinase activity. In addition, CADM1 downregulation markedly increased tyrosine phosphorylation of protein bands 58–63 kDa. Some of them are likely to be SRC family kinases Lyn (59 kDa) and Fyn (61 kDa), which bind to activated Kit [69] and become more tyrosine phosphorylated upon recruitment. Similarly, we found some evidence of reduced levels of actin polymerisation and tyrosine phosphorylation in two populations of HLMCs with downregulated CADM1.
Altogether, CADM1 upregulation increased surface Kit and reduced its kinase activity and, vice versa, CADM1 downregulation decreased surface Kit and increased its activation in HMC-1 cells that have mutated Kit V560G. Since CADM1 and Kit co-precipitate [20], it is possible that CADM1 physically interacts with a particular inactive conformation of Kit, and as a result, increased CADM1 levels would stabilise Kit in this conformation on the cell surface. Conversely, decreased CADM1 would not stabilise inactive Kit; thus, mutated Kit would dimerise and autophosphorylate C-terminal tyrosines, this would result in increased internalisation of Kit and removal from the cell surface. This potential mechanism requires further investigation, because it may have functional implications for the pathophysiology of leukaemia and pulmonary fibrosis. Interestingly, high levels CADM1 in mixed-lineage leukaemia-rearranged acute monoblastic leukaemia provide better overall survival [70]. Expression of Kit was also reported in this disease [71]. Recent data suggest that lung fibroblasts express increased levels of membranous SCF, the Kit ligand, in pulmonary fibrosis [22]. Their co-culture with HLMCs results in increased activation and proliferation of both cell types [22], driving the progression of disease.
Although a connection between CADM1 and F-actin was proposed some time ago [44], we did not find published data demonstrating the reorganisation of the actin cytoskeleton by CADM1. We show that polymerisation of actin i) positively correlates with CADM1 levels, ii) depends on the expressed isoforms SP4 or SP1 and iii) affects the length of cortical actin filaments in human mast cells. We have shown previously that SP4 and SP1 isoforms are functionally different in regard to mast cell survival and expression of anti-apoptotic protein MCL-1 [38], homotypic mast cell adhesion [38], and mast cell adhesion to human lung fibroblasts [19], [39]. This study shows that these isoforms also affect F-actin assembly differentially. Since the SP4 and SP1 isoforms differ only by 11 amino acids in the extracellular domain, their effects on intracellular events may be a result of their differential shedding, thus leading to altered cell signalling for SP1 compared to SP4.
CADM1-induced modulation of the actin cytoskeleton determined its flexibility in HMC-1 cells flattened between glass slides and coverslips. Interestingly, CADM1 downregulation also resulted in a flat morphology of epithelial HEK293 cells and impaired filopodia formation in neurons [47], [51]. Since CADM1 is responsible only for ∼30% of F-actin and is connected to the actin cytoskeleton indirectly via linker proteins, it is feasible that these proteins organise local points for actin polymerisation with actin filaments extending outwards along the cell membrane; this would explain the relatively limited colocalisation of CADM1 and F-actin.
Functional links between proteins necessitate their localisation in the same cell compartments. Since CADM1 was responsible for a substantial portion of surface Kit and F-actin levels, we expected to find partial colocalisation of them with CADM1. The Manders’s coefficient M1 for colocalisation of surface Kit with CADM1 was higher than M1 for colocalisation of F-actin with CADM1 in all groups of HMC-1 cells; thus it was consistent with FACS data indicating that CADM1 is responsible for a half of Kit and only a third of cortical F-actin on the cell surface. In contrast, in the control LucSh-transduced cells the Manders’ coefficients M2 for colocalisation of CADM1 with Kit or F-actin were lower than the corresponding M1 coefficients for colocalisation of these proteins with CADM1, indicating that CADM1 participates in formation of multiple other protein complexes on the cell surface. Both data from microscopy (Manders’s coefficient) and FACS suggest some functional relationships between CADM1 and Kit/F-actin; therefore, further studies are required to elucidate their interactions at a molecular level.
Re-arrangement of the actin cytoskeleton affects various cell functions. In MCs it may influence two critical processes: migration and secretion. An ability to change cell shape is important for MCs in order to i) migrate from bone marrow into specific tissue sites through multiple layers of various cells and matrices, and ii) redistribute to the key positions in infection or diseases. MCs with reduced CADM1 are likely to migrate with less efficiency, because they have lower adhesion capacity and a more rigid cell shape. MCs are specialised secretory cells and degranulation involves extensive cytoskeleton reorganisation [72]. Therefore, rearrangement of actin filaments in MCs with reduced CADM1 may affect secretion. The role of CADM1 in these specialised MC functions requires future studies.
Collectively our data show for the first time that CADM1 is not only a major human MC adhesion receptor involved in cell-cell and cell-ECM adhesion, but it also controls the assembly of actin filaments and docks Kit at the cell surface. On this basis we propose a stepwise model of MC adhesion, which includes interactions between various receptors and Kit ( Fig. 8 ). According to this model, CADM1 provides initial adhesion between human MCs and HASMCs and, as a result, ECM receptors are positioned in close proximity to ECM on the surface of HASMCs, thereby facilitating the adhesive interaction of other adhesion receptors. Integrin engagement is also facilitated by quick anchoring of integrin-mediated adhesion complexes to the actin cytoskeleton, which is partly dependent on CADM1. Furthermore, surface Kit stabilised by CADM1, binds membranous SCF on HASMCs, becomes activated and initiates phosphotyrosine signalling to cross-activate ECM adhesion receptors. Whether activated Kit is bound to CADM1 at this stage needs further examination. Overall, CADM1 influences several parameters in cells which facilitate cell adhesion through other receptors.
It is becoming increasingly obvious that cell adhesion involves a variety of cooperating adhesion receptors and growth factor receptor tyrosine kinases [63]. CADM1 is not just one of them, it is a receptor which is likely to organise other adhesion receptors and signalling complexes at the MC membrane. Therefore, future studies should elucidate the exact structure of CADM1-binding complexes and interactions between them in order to understand cross-talk between various adhesion receptors and links to Kit-mediated phosphotyrosine signalling in mast and other cell types.
Supporting Information
Acknowledgments
The authors are grateful to Prof. Brightling for providing HASMCs, to Dan Deeping and Bhavna Godhaniya for preparation of HLMCs and Adelina Gavrila for preparation and HASMCs. We also thank Dr Christopher Newby for the advice on the statistical analysis and help with regression models.
Funding Statement
This work is supported by project grant no. 87834 from the Medical Research Council, United Kingdom (PB and MLL) and was also supported in part by the National Institute for Health Research Leicester Respiratory Biomedical Research Unit. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute of Health Research or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Shelburne CP, Abraham SN (2011) The mast cell in innate and adaptive immunity. Adv Exp Med Biol 716: 162–185. [DOI] [PubMed] [Google Scholar]
- 2. Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 40: 1843–1851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Moiseeva EP, Bradding P (2011) Mast cells in lung inflammation. Adv Exp Med Biol 716: 235–269. [DOI] [PubMed] [Google Scholar]
- 4. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, et al. (2012) Mast cells and inflammation. Biochim Biophys Acta 1822: 21–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Yu M, Eckart MR, Morgan AA, Mukai K, Butte AJ, et al. (2011) Identification of an IFN-gamma/mast cell axis in a mouse model of chronic asthma. J Clin Invest 121: 3133–3143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Sperr WR, Agis H, Czerwenka K, Klepetko W, Kubista E, et al. (1992) Differential expression of cell surface integrins on human mast cells and human basophils. Ann Hematol 65: 10–16. [DOI] [PubMed] [Google Scholar]
- 7. Kruger-Krasagakes S, Grutzkau A, Baghramian R, Henz BM (1996) Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins. J Invest Dermatol 106: 538–543. [DOI] [PubMed] [Google Scholar]
- 8. Toru H, Kinashi T, Ra C, Nonoyama S, Yata J, et al. (1997) Interleukin-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules. Blood 89: 3296–3302. [PubMed] [Google Scholar]
- 9. Trautmann A, Feuerstein B, Ernst N, Brocker EB, Klein CE (1997) Heterotypic cell-cell adhesion of human mast cells to fibroblasts. Arch Dermatol Res 289: 194–203. [DOI] [PubMed] [Google Scholar]
- 10. Sanmugalingam D, Wardlaw AJ, Bradding P (2000) Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism. J Leukoc Biol 68: 38–46. [PubMed] [Google Scholar]
- 11. Tachimoto H, Hudson SA, Bochner BS (2001) Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation. J Allergy Clin Immunol 107: 302–309. [DOI] [PubMed] [Google Scholar]
- 12. Yang W, Kaur D, Okayama Y, Ito A, Wardlaw AJ, et al. (2006) Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1. J Immunol 176: 1238–1243. [DOI] [PubMed] [Google Scholar]
- 13. Nishida M, Kawai K, Tanaka M, Tegoshi T, Arizono N (2003) Expression of E-cadherin in human mast cell line HMC-1. Apmis 111: 1067–1074. [DOI] [PubMed] [Google Scholar]
- 14. Kashiwakura J, Yokoi H, Saito H, Okayama Y (2004) T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 173: 5247–5257. [DOI] [PubMed] [Google Scholar]
- 15. Florian S, Sonneck K, Czerny M, Hennersdorf F, Hauswirth AW, et al. (2006) Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 61: 1054–1062. [DOI] [PubMed] [Google Scholar]
- 16. Bradding P (2009) Human lung mast cell heterogeneity. Thorax 64: 278–280. [DOI] [PubMed] [Google Scholar]
- 17. Ito A, Jippo T, Wakayama T, Morii E, Koma Y, et al. (2003) SgIGSF: a new mast-cell adhesion molecule used for attachment to fibroblasts and transcriptionally regulated by MITF. Blood 101: 2601–2608. [DOI] [PubMed] [Google Scholar]
- 18. Furuno T, Ito A, Koma Y, Watabe K, Yokozaki H, et al. (2005) The spermatogenic Ig superfamily/synaptic cell adhesion molecule mast-cell adhesion molecule promotes interaction with nerves. J Immunol 174: 6934–6942. [DOI] [PubMed] [Google Scholar]
- 19. Moiseeva EP, Roach KM, Leyland ML, Bradding P (2013) CADM1 Is a Key Receptor Mediating Human Mast Cell Adhesion to Human Lung Fibroblasts and Airway Smooth Muscle Cells. PLoS One 8: e61579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Hollins F, Kaur D, Yang W, Cruse G, Saunders R, et al. (2008) Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6. J Immunol 181: 2772–2780. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Woodman L, Siddiqui S, Cruse G, Sutcliffe A, Saunders R, et al. (2008) Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1. J Immunol 181: 5001–5007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Wygrecka M, Dahal BK, Kosanovic D, Petersen F, Taborski B, et al. (2013) Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-alpha/Raf-1/p44/42 signaling pathway. Am J Pathol 182: 2094–2108. [DOI] [PubMed] [Google Scholar]
- 23. Flicek P, Amode MR, Barrell D, Beal K, Brent S, et al. (2011) Ensembl 2011. Nucleic Acids Res 39: D800–806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Gomyo H, Arai Y, Tanigami A, Murakami Y, Hattori M, et al. (1999) A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11q23.2. Genomics 62: 139–146. [DOI] [PubMed] [Google Scholar]
- 25. Zhiling Y, Fujita E, Tanabe Y, Yamagata T, Momoi T, et al. (2008) Mutations in the gene encoding CADM1 are associated with autism spectrum disorder. Biochem Biophys Res Commun 377: 926–929. [DOI] [PubMed] [Google Scholar]
- 26. Hasstedt SJ, Bezemer ID, Callas PW, Vossen CY, Trotman W, et al. (2009) Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 114: 3084–3091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. van der Weyden L, Arends MJ, Rust AG, Poulogiannis G, McIntyre RE, et al. (2012) Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1. Mol Cancer 11: 29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Paun A, Haston CK (2012) Genomic and genome-wide association of susceptibility to radiation-induced fibrotic lung disease in mice. Radiother Oncol 105: 350–357. [DOI] [PubMed] [Google Scholar]
- 29. Bassett JH, Gogakos A, White JK, Evans H, Jacques RM, et al. (2012) Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet 8: e1002858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, et al. (2002) The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 277: 31014–31019. [DOI] [PubMed] [Google Scholar]
- 31. Shingai T, Ikeda W, Kakunaga S, Morimoto K, Takekuni K, et al. (2003) Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem 278: 35421–35427. [DOI] [PubMed] [Google Scholar]
- 32. Galibert L, Diemer GS, Liu Z, Johnson RS, Smith JL, et al. (2005) Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J Biol Chem 280: 21955–21964. [DOI] [PubMed] [Google Scholar]
- 33. Fogel AI, Akins MR, Krupp AJ, Stagi M, Stein V, et al. (2007) SynCAMs organize synapses through heterophilic adhesion. J Neurosci 27: 12516–12530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM (2009) Necl2 regulates epidermal adhesion and wound repair. Development 136: 3505–3514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Mizutani K, Kawano S, Minami A, Waseda M, Ikeda W, et al. (2011) Interaction of nectin-like molecule 2 with integrin alpha6beta4 and inhibition of disassembly of integrin alpha6beta4 from hemidesmosomes. J Biol Chem 286: 36667–36676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y (2007) The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol 19: 593–602. [DOI] [PubMed] [Google Scholar]
- 37. Takai Y, Miyoshi J, Ikeda W, Ogita H (2008) Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9: 603–615. [DOI] [PubMed] [Google Scholar]
- 38. Moiseeva EP, Leyland ML, Bradding P (2012) CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion. Cell Mol Life Sci 69: 2751–2764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Moiseeva EP, Leyland ML, Bradding P (2013) CADM1 is expressed as multiple alternatively spliced functional and dysfunctional isoforms in human mast cells. Mol Immunol 53: 345–354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Kaur D, Saunders R, Hollins F, Woodman L, Doe C, et al. (2010) Mast Cell Fibroblastoid Differentiation Mediated by Airway Smooth Muscle in Asthma. J Immunol 185: 6105–6114. [DOI] [PubMed] [Google Scholar]
- 41. Girodet PO, Ozier A, Trian T, Begueret H, Ousova O, et al. (2010) Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6. Allergy 65: 1004–1012. [DOI] [PubMed] [Google Scholar]
- 42. Kawano S, Ikeda W, Kishimoto M, Ogita H, Takai Y (2009) Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. J Biol Chem 284: 23793–23805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Ito A, Koma Y, Watabe K, Jippo T, Wakayama T, et al. (2004) Contribution of the SgIGSF adhesion molecule to survival of cultured mast cells in vivo. Biochem Biophys Res Commun 319: 200–206. [DOI] [PubMed] [Google Scholar]
- 44. Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, et al. (2002) Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 62: 5129–5133. [PubMed] [Google Scholar]
- 45. Terada N, Ohno N, Saitoh S, Saitoh Y, Komada M, et al. (2010) Involvement of a membrane skeletal protein, 4.1G, for Sertoli/germ cell interaction. Reproduction 139: 883–892. [DOI] [PubMed] [Google Scholar]
- 46. Hoy JL, Constable JR, Vicini S, Fu Z, Washbourne P (2009) SynCAM1 recruits NMDA receptors via protein 4.1B. Mol Cell Neurosci 42: 466–483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Stagi M, Fogel AI, Biederer T (2010) SynCAM 1 participates in axo-dendritic contact assembly and shapes neuronal growth cones. Proc Natl Acad Sci U S A 107: 7568–7573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, et al. (2002) SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297: 1525–1531. [DOI] [PubMed] [Google Scholar]
- 49. Fukuhara H, Masuda M, Yageta M, Fukami T, Kuramochi M, et al. (2003) Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene 22: 6160–6165. [DOI] [PubMed] [Google Scholar]
- 50. Masuda M, Maruyama T, Ohta T, Ito A, Hayashi T, et al. (2010) CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem 285: 15511–15522. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Sakurai-Yageta M, Masuda M, Tsuboi Y, Ito A, Murakami Y (2009) Tumor suppressor CADM1 is involved in epithelial cell structure. Biochem Biophys Res Commun 390: 977–982. [DOI] [PubMed] [Google Scholar]
- 52. Biederer T, Sudhof TC (2001) CASK and protein 4.1 support F-actin nucleation on neurexins. J Biol Chem 276: 47869–47876. [DOI] [PubMed] [Google Scholar]
- 53. Butterfield JH, Weiler D, Dewald G, Gleich GJ (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12: 345–355. [DOI] [PubMed] [Google Scholar]
- 54. Kaur D, Saunders R, Berger P, Siddiqui S, Woodman L, et al. (2006) Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am J Respir Crit Care Med 174: 1179–1188. [DOI] [PubMed] [Google Scholar]
- 55. Moiseeva EP, Javed Q, Spring EL, de Bono DP (2000) Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 45: 493–502. [DOI] [PubMed] [Google Scholar]
- 56. Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, et al. (1989) Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 49: 2128–2133. [PubMed] [Google Scholar]
- 57. Morgan MR, Humphries MJ, Bass MD (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 8: 957–969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Lorentz A, Schuppan D, Gebert A, Manns MP, Bischoff SC (2002) Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood 99: 966–972. [DOI] [PubMed] [Google Scholar]
- 59. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213–232. [DOI] [PubMed] [Google Scholar]
- 60. Barlow AL, Macleod A, Noppen S, Sanderson J, Guerin CJ (2010) Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of pearson’s correlation coefficient. Microsc Microanal 16: 710–724. [DOI] [PubMed] [Google Scholar]
- 61. Adler J, Parmryd I (2010) Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander’s overlap coefficient. Cytometry A 77: 733–742. [DOI] [PubMed] [Google Scholar]
- 62. Yang YX, Yang AH, Yang ZJ, Wang ZR, Xia XH (2006) Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis. Int J Gynecol Cancer 16: 1868–1872. [DOI] [PubMed] [Google Scholar]
- 63. Byron A, Morgan MR, Humphries MJ (2010) Adhesion signalling complexes. Curr Biol 20: R1063–1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Takeuchi K, Koike K, Kamijo T, Ishida S, Nakazawa Y, et al. (2003) STI571 inhibits growth and adhesion of human mast cells in culture. J Leukoc Biol 74: 1026–1034. [DOI] [PubMed] [Google Scholar]
- 65. Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM (2008) Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 324: 128–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Columbo M, Bochner BS, Marone G (1995) Human skin mast cells express functional beta 1 integrins that mediate adhesion to extracellular matrix proteins. J Immunol 154: 6058–6064. [PubMed] [Google Scholar]
- 67. Shimizu Y, Sakai K, Miura T, Narita T, Tsukagoshi H, et al. (2002) Characterization of ‘adult-type’ mast cells derived from human bone marrow CD34(+) cells cultured in the presence of stem cell factor and interleukin-6. Interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation. Clin Exp Allergy 32: 872–880. [DOI] [PubMed] [Google Scholar]
- 68. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2011) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 39: D38–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Gilfillan AM, Rivera J (2009) The tyrosine kinase network regulating mast cell activation. Immunol Rev 228: 149–169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Kuipers JE, Coenen EA, Balgobind BV, Stary J, Baruchel A, et al. (2011) High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Blood 117: 928–935. [DOI] [PubMed] [Google Scholar]
- 71. Classen CF, Teigler-Schlegel A, Rottgers S, Reinhardt D, Dohner K, et al. (2005) AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Ann Hematol 84: 774–780. [DOI] [PubMed] [Google Scholar]
- 72. Blank U (2011) The mechanisms of exocytosis in mast cells. Adv Exp Med Biol 716: 107–122. [DOI] [PubMed] [Google Scholar]
- 73. Ogita H, Rikitake Y, Miyoshi J, Takai Y (2010) Cell adhesion molecules nectins and associating proteins: Implications for physiology and pathology. Proc Jpn Acad Ser B Phys Biol Sci 86: 621–629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, et al. (2007) Vinculin controls focal adhesion formation by direct interactions with talin and actin. J Cell Biol 179: 1043–1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.